vaccin
singl
effect
way
control
viral
diseas
howev
mani
current
use
vaccin
safeti
concern
efficaci
issu
product
problem
viral
pathogen
classic
approach
vaccin
develop
thu
far
unsuccess
viruslik
particl
vlp
increasingli
consid
vaccin
candid
offer
signific
advantag
mani
current
use
vaccin
develop
vaccin
technolog
vlp
form
structur
protein
newcastl
diseas
viru
avian
paramyxoviru
potenti
vaccin
candid
newcastl
diseas
poultri
importantli
vlp
novel
uniqu
versatil
vlp
platform
rapid
construct
effect
vaccin
candid
mani
human
pathogen
includ
genet
complex
virus
virus
vaccin
current
exist
pathogen
vaccin
pathogen
vaccin
exist
rapidli
produc
vaccin
emerg
threat
viruslik
particl
vlp
particularli
versatil
vlp
vaccin
platform
newcastl
diseas
vlp
describ
articl
potenti
solut
develop
altern
safer
vaccin
vaccin
previous
intract
pathogen
licens
viral
vaccin
either
live
attenu
inactiv
virus
live
attenu
virus
consid
effect
vaccin
howev
liveviru
vaccin
may
caus
diseas
immunocompromis
individu
consider
increas
concern
owe
hiv
pandem
organ
transplant
well
cancer
chemotherapi
live
virus
also
potenti
revert
virul
form
albeit
low
frequenc
recombin
endem
virus
produc
potenti
virul
viru
contamin
vaccin
virus
still
problem
recent
document
one
newli
approv
rotaviru
vaccin
recombin
live
avirul
virus
contain
foreign
gene
engin
genom
also
current
develop
promis
vaccin
candid
review
exampl
howev
live
avirul
vector
virus
may
also
pose
risk
immunocompromis
popul
addit
vector
virus
may
stimul
undesir
abnorm
immun
respons
review
inactiv
vaccin
safer
produc
poorer
shorterliv
immun
respons
live
viru
part
owe
alter
immunogen
viral
protein
inactiv
review
furthermor
inactiv
vaccin
viru
prepar
requir
product
larg
quantiti
virul
virus
certain
virus
requir
special
contain
measur
danger
product
personnel
virus
avian
influenza
viru
difficult
produc
larg
quantiti
owe
virul
ineffici
product
tissu
cultur
system
addit
vaccin
inactiv
virus
exampl
rsv
measl
viru
actual
exacerb
diseas
upon
subsequ
exposur
live
viru
review
type
vaccin
develop
purifi
protein
dna
replicon
replicationdefect
vaccin
purifi
protein
usual
effect
without
adjuv
adjuv
licens
use
human
mani
dna
vaccin
activ
develop
none
yet
licens
use
human
review
furthermor
human
trial
immun
respons
report
weak
without
addit
immun
replicon
vaccin
defect
genom
foreign
gene
introduc
eg
capabl
singl
cycl
infect
defect
genom
may
replic
persist
extend
period
infect
cell
increas
risk
recombin
replicon
endem
viru
gener
virul
viru
viruslik
particl
increasingli
consid
viral
vaccin
review
although
potenti
exploit
two
vlp
vaccin
current
licens
use
human
popul
describ
vlp
compos
capsid
protein
approv
papilloma
viru
hpv
vaccin
hbv
vaccin
particl
produc
yeast
compos
membran
hbv
surfac
antigen
vaccin
illustr
two
gener
type
vlp
form
protein
nonenvelop
virus
form
protein
deriv
envelop
virus
viruslik
particl
vaccin
may
offer
signific
advantag
mani
current
use
vaccin
develop
vaccin
technolog
vlp
form
assembl
viral
structur
protein
lipid
particl
without
incorpor
viral
genom
thu
vlp
incap
spread
infect
typic
infecti
viru
elimin
danger
diseas
immunocompromis
individu
chanc
revers
virul
recombin
endem
virus
sinc
genom
present
product
vlp
hazard
sinc
live
viru
involv
prepar
importantli
vlp
potent
immunogen
sinc
particl
similar
size
virus
contain
repeat
protein
array
surfac
core
mimic
infecti
virus
structur
account
part
potent
immunogen
virus
furthermor
sinc
assembl
particl
assembl
virus
requir
correct
fold
protein
vlp
like
contain
mani
authent
antigen
site
sinc
inactiv
vlp
requir
import
epitop
retain
new
one
probabl
gener
importantli
contrast
mani
viru
vaccin
vlp
may
form
without
viral
protein
downregul
host
immun
respons
addit
licens
hpv
hbv
vlp
vaccin
number
vlp
test
potenti
vaccin
candid
preclin
studi
immun
respons
efficaci
mani
vlp
vaccin
candid
provid
encourag
result
recent
exampl
studi
includ
character
ebola
viru
vlp
season
pandem
influenza
vlp
chikungunya
viru
vlp
hiv
vlp
hcv
vlp
summar
mani
excel
review
eg
wellcharacter
vlp
potent
stimul
immun
respons
surfac
protein
usual
stimul
neutral
antibodi
owe
particul
natur
vlp
taken
process
present
mhc
class
class
ii
pathway
result
broad
rang
tcell
respons
key
import
vlp
describ
selfadjuv
adjuv
requir
immun
respons
system
respons
usual
translat
vaccin
candid
provid
impress
safe
protect
experiment
anim
challeng
live
virul
virus
viru
system
produc
vlp
viral
system
yield
vlp
level
like
suffici
use
immunogen
extend
use
establish
wellcharacter
vlp
vaccin
virus
sever
approach
report
passiv
incorpor
glycoprotein
vlp
form
retroviru
gag
protein
report
review
illustr
immunodomin
molecul
chemic
crosslink
surfac
vlp
final
key
neutral
antibodi
tcell
epitop
target
viru
genet
fuse
structur
protein
wellcharacter
vlp
mani
variat
last
approach
recent
exampl
includ
chimera
vlp
report
retroviru
gag
hbcag
hbsag
vlp
efficaci
chimera
vlp
protect
target
pathogen
less
extens
character
develop
vlp
form
structur
protein
avian
paramyxoviru
newcastl
diseas
viru
vaccin
vaccin
platform
paramyxovirus
envelop
negativestrand
rna
virus
paramyxoviru
virion
figur
contain
least
two
glycoprotein
attach
protein
term
hemagglutininneuraminidas
hn
protein
newcastl
diseas
viru
fusion
f
protein
direct
fusion
viral
cellular
membran
line
inner
surfac
membran
matrix
membran
protein
core
viru
contain
genom
rna
three
associ
protein
nucleocapsid
protein
np
bind
rna
genom
phosphoprotein
p
viral
polymeras
larg
l
protein
report
mani
differ
paramyxoviru
vlp
produc
upon
express
protein
protein
variou
combin
glycoprotein
np
inde
depict
figur
cell
express
newcastl
diseas
viru
hn
f
np
protein
releas
particl
structur
function
resembl
viru
particl
distinguish
newcastl
diseas
vlp
paramyxoviru
vlp
inde
mani
type
vlp
strike
effici
releas
report
effici
releas
paramyxoviru
vlp
measur
effici
protein
releas
rang
newcastl
diseas
vlp
releas
result
quantit
amount
newcastl
diseas
vlp
rel
easi
prepar
even
transient
transfect
cell
purifi
use
protocol
util
viru
purif
purifi
vlp
minim
cell
protein
contamin
figur
furthermor
ratio
viral
protein
similar
viru
particl
figur
glycoprotein
assembl
newcastl
diseas
vlp
like
authent
conform
stringent
test
conform
glycoprotein
preserv
biolog
activ
virionassoci
glycoprotein
inde
hn
protein
associ
newcastl
diseas
vlp
mediat
cell
bind
possess
neuraminidas
activ
hn
protein
associ
particl
also
direct
hemagglutin
titer
compar
equival
amount
viru
f
protein
particl
direct
fusion
vlp
membran
red
blood
cell
membran
effect
newcastl
diseas
vlp
immunogen
demonstr
murin
model
compar
respons
stimul
immun
compar
amount
uvinactiv
vaccin
strain
newcastl
diseas
viru
level
solubl
antibodi
character
elisa
neutral
antibodi
titer
result
newcastl
diseas
vlp
immun
high
higher
result
immun
vaccin
viru
furthermor
newcastl
diseas
vlp
stimul
tcell
respons
level
slightli
higher
stimul
vaccin
viru
thu
newcastl
diseas
vlp
exhibit
characterist
effect
vaccin
potenti
veterinari
vaccin
candid
newcastl
diseas
poultri
current
problem
avail
newcastl
diseas
viru
vaccin
failur
vaccin
virus
protect
period
outbreak
virul
exot
strain
viru
domest
chicken
flock
howev
newcastl
diseas
vlp
potenti
broadspectrum
newcastl
diseas
viru
vaccin
could
provid
protect
mani
newcastl
diseas
viru
strain
includ
exot
strain
sinc
found
glycoprotein
differ
strain
newcastl
diseas
viru
incorpor
particl
newcastl
diseas
vlp
signific
potenti
applic
beyond
newcastl
diseas
viru
vaccin
newcastl
diseas
vlp
novel
uniqu
versatil
vlp
platform
rapid
construct
effect
vaccin
candid
mani
human
pathogen
includ
genet
complex
virus
describ
vlp
newcastl
diseas
vlp
use
express
peptid
sequenc
target
pathogen
inde
shown
vlp
assembl
unaffect
genet
fusion
foreign
sequenc
amino
terminu
carboxyl
terminu
newcastl
diseas
viru
np
protein
cterminu
hn
protein
rais
possibl
use
vlp
present
domain
stimul
neutral
antibodi
tcell
respons
importantli
newcastl
diseas
vlp
use
present
entir
ectodomain
glycoprotein
mani
differ
virus
newcastl
diseas
viru
glycoprotein
assembl
vlp
owe
specif
interact
glycoprotein
cytoplasm
ct
transmembran
tm
domain
newcastl
diseas
viru
core
protein
ectodomain
littl
influenc
assembl
morrison
tg
et
al
unpublish
data
thu
specif
incorpor
foreign
glycoprotein
ectodomain
newcastl
diseas
vlp
achiev
construct
chimera
protein
gene
compos
sequenc
encod
foreign
protein
ectodomain
fuse
encod
tm
ct
domain
appropri
newcastl
diseas
viru
glycoprotein
figur
type
type
glycoprotein
assembl
particl
way
owe
properti
newcastl
diseas
viru
glycoprotein
f
protein
type
glycoprotein
hn
protein
type
glycoprotein
thu
foreign
type
glycoprotein
ectodomain
fuse
tm
ct
domain
f
protein
type
glycoprotein
ectodomain
fuse
ct
tm
domain
hn
protein
figur
specif
assembl
entir
ectodomain
protein
rather
short
peptid
domain
like
result
properli
fold
protein
authent
posttransl
modif
conform
epitop
tcell
epitop
includ
yet
identifi
inde
use
approach
success
incorpor
newcastl
diseas
vlp
entir
ectodomain
nipah
viru
g
protein
rsv
g
protein
type
glycoprotein
figur
figur
illustr
incorpor
ectodomain
cmv
gb
glycoprotein
furthermor
incorpor
singl
particl
prepar
cmv
gb
rsv
g
protein
ectodomain
figur
rais
possibl
newcastl
diseas
vlp
could
use
singl
vaccin
specif
two
differ
pathogen
exampl
assembl
newcastl
diseas
viru
hn
protein
influenza
ha
protein
singl
vlp
could
use
protect
chicken
avian
influenza
newcastl
diseas
viru
assembl
rsv
g
protein
influenza
ha
protein
singl
particl
could
protect
human
popul
rsv
influenza
test
potenti
newcastl
diseas
vlp
contain
foreign
glycoprotein
ectodomain
vaccin
vlp
contain
ectodomain
rsv
g
protein
vlp
contain
ectodomain
rsv
g
f
protein
use
immunogen
without
adjuv
murin
system
immun
either
intraperiton
intramuscular
inocul
vlp
contain
g
protein
ectodomain
stimul
antirsv
g
protein
antibodi
level
compar
higher
level
result
live
viru
infect
immun
uvinactiv
viru
immun
vlp
provid
complet
protect
rsv
replic
lung
intranas
challeng
live
viru
figur
vlp
contain
ectodomain
rsv
g
f
protein
stimul
mice
high
titer
antibodi
g
owe
fact
variou
form
nonrepl
rsv
immunogen
includ
formalininactiv
viru
firsv
report
stimul
enhanc
lung
patholog
upon
liveviru
challeng
effect
immun
either
vlp
formul
lung
patholog
assess
neither
vlp
stimul
enhanc
respiratori
diseas
attribut
abnorm
immun
respons
firsv
parallel
immun
describ
detail
murawski
et
al
morrison
tg
et
al
unpublish
data
suggest
safeti
type
rsv
vaccin
addit
consider
suggest
vlp
form
newcastl
diseas
viru
protein
would
effect
yet
safe
human
vaccin
newcastl
diseas
viru
avian
pathogen
report
newcastl
diseas
viru
caus
human
diseas
gener
popul
report
seroposit
human
popul
thu
previous
exist
immun
interfer
immun
respons
evid
advers
effect
human
due
viral
antigen
inde
live
newcastl
diseas
viru
inject
intraven
human
clinic
trial
test
newcastl
diseas
viru
oncolyt
agent
studi
report
littl
toxic
newcastl
diseas
viru
vlp
would
therefor
ideal
framework
base
human
vaccin
like
near
futur
mani
vlp
licens
use
vaccin
human
agricultur
anim
newcastl
diseas
vlp
well
type
vlp
show
signific
promis
preclin
studi
next
step
translat
posit
preclin
result
vaccin
trial
licensur
human
agricultur
vaccin
requir
vlp
produc
costeffect
manner
larg
scale
good
manufactur
process
step
next
major
challeng
continu
develop
vlp
vaccin
particularli
envelop
vlp
review
newcastl
diseas
vlp
howev
vlp
form
influenza
protein
ebola
viru
protein
produc
insect
cell
use
baculoviru
vector
eg
system
easili
adapt
largescal
product
mani
vlp
issu
surround
vlp
product
baculoviru
vectorinfect
insect
cell
involv
alter
carbohydr
modif
glycoprotein
synthes
insect
cell
discuss
contamin
baculovirus
vlp
prepar
discuss
howev
influenza
vlp
form
way
clinic
trial
altern
system
util
tissu
cultur
cell
approv
use
vaccin
product
could
also
adapt
product
vlp
cell
line
deriv
approv
cell
express
vlp
protein
may
produc
altern
largescal
transient
transfect
explor
purif
vlp
mammalian
cell
would
elimin
issu
immunogen
associ
alter
posttransl
modif
protein
produc
insect
cell
would
elimin
concern
presenc
baculovirus
vaccin
prepar
note
vaccin
candid
stimul
effect
immun
respons
anim
model
fail
human
problem
exemplifi
clinic
trial
potenti
human
rsv
vaccin
candid
review
howev
mani
vlp
vaccin
candid
test
human
trial
stimul
robust
immun
respons
indic
approach
vaccin
develop
great
potenti
furthermor
character
immun
respons
vlp
includ
chimera
newcastl
diseas
vlp
newli
develop
human
mous
model
may
facilit
path
vlp
vaccin
candid
clinic
trial
system
potenti
assess
directli
human
immun
respons
preclin
develop
vlp
vaccin
candid
challeng
vaccin
develop
new
safer
vaccin
need
replac
old
one
vaccin
need
develop
pathogen
vaccin
exist
way
rapidli
produc
vaccin
newli
emerg
threat
need
develop
live
attenu
viru
vaccin
effect
danger
inactiv
viru
vaccin
usual
safer
often
less
effect
mani
newer
approach
vaccin
develop
also
inher
problem
viruslik
particl
vlp
particl
resembl
viru
particl
genom
vlp
immunogen
vlp
vaccin
offer
mani
advantag
vaccin
technolog
vlp
stimul
neutral
antibodi
divers
tcell
respons
adjuv
requir
immun
respons
stimul
vlp
vlp
use
platform
present
antigen
differ
pathogen
vlp
releas
strike
effici
cell
express
newcastl
diseas
viru
nucleocapsid
membran
hemagglutininneuraminidas
fusion
protein
newcastl
diseas
vlp
resembl
viru
glycoprotein
retain
activ
newcastl
diseas
vlp
stimul
humor
cellular
immun
respons
compar
vaccin
viru
glycoprotein
differ
strain
newcastl
diseas
viru
incorpor
newcastl
diseas
vlp
newcastl
diseas
vlp
uniqu
versatil
vaccin
platform
short
foreign
sequenc
genet
fuse
end
nucleocapsid
hemagglutininneuraminidas
protein
entir
ectodomain
differ
foreign
glycoprotein
assembl
newcastl
diseas
vlp
chimera
newcastl
diseas
vlp
stimul
immun
respons
compar
live
viru
infect
immun
chimera
newcastl
diseas
vlp
provid
complet
protect
upon
live
viru
challeng
anim
model
increas
number
vlp
vaccin
like
licens
near
futur
develop
newcastl
diseas
vlp
vaccin
requir
largescal
product
effect
newcastl
diseas
vlp
vaccin
human
explor
util
human
mous
model
vlp
harvest
supernat
cell
express
newcastl
diseas
np
hn
f
protein
purifi
sequenti
sediment
flotat
protocol
similar
use
viru
purif
describ
pantua
et
al
mcginn
et
al
protein
purifi
vlp
separ
electrophoresi
polyacrylamid
gel
detect
silver
stain
compar
protein
equival
amount
purifi
avirul
vaccin
viru
grown
embryon
chicken
egg
protein
shown
lane
separ
polyacrylamid
gel
absenc
reduc
agent
order
resolv
disulfid
link
f
vlp
contain
hg
chimera
protein
newcastl
diseas
viru
nucleocapsid
protein
membran
protein
use
immunogen
balbc
mice
previous
describ
vlp
total
vlp
proteinanim
deliv
intraperiton
inocul
similar
result
obtain
use
intramuscular
immun
parallel
group
mice
receiv
immun
infect
live
rsv
pfuanim
deliv
intranas
immun
mice
challeng
infecti
rsv
pfuanim
viru
titer
lung
measur
day
postchalleng
result
show
viru
titersg
lung
tissu
mous
group
rsv
respiratori
syncyti
viru
vlp
viruslik
particl
adapt
permiss
american
societi
microbiolog
